Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript

SA Transcripts158.8K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call March 4, 2026 4:30 PM EST Company Participants Kendall Knysch - Head of Media Relations & PartnershipsRobert Fried - CEO & DirectorAndrew Shao - Senior Vice President of Global Regulatory & Scientific AffairsOzan Pamir - CFO & Principal Accounting OfficerLauren Rittman-Borzansky Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research DivisionSusan Anderson - Canaccord Genuity Corp., Research DivisionRaghuram Selvaraju - H.C. Wainwright & Co, LLC, Research DivisionSean McGowan - ROTH Capital Partners, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience, Inc. Fourth Quarter of 2025 Earnings Conference Call. My name is Tiffany, and I will be the conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. This afternoon, Niagen Bioscience issued a news release announcing the company's financial results for the fourth quarter of 2025. If you have not reviewed this information, both are available within the Investor Relations section of Niagen Bioscience website at www.niagenbioscience.com. I would now like to turn the conference call over to Kendall Knysch, Senior Director of Publicity and Public Relations. Please go ahead, Ms. Knysch. Kendall KnyschHead of Media Relations & Partnerships Thank you. Good afternoon, and welcome to Niagen Bioscience Inc.'s Fourth Quarter of 2025 Results Investor Call. With us today are Niagen Biosciences' Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Today's conference call may include forward-looking statements, including statements related to the company's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Niagen products and ingredients in new markets, business development opportunities, future financial